Lack of Effect on Survival of High-Dose Acyclovir and Zidovudine Compared with Zidovudine Alone for Acquired Immunodeficiency Syndrome

To evaluate the effect of acyclovir on survival of adults with moderately advanced human immunodeficiency virus type 1 (HIV-1) infection, a randomized, double-blind, placebo-controlled study was conducted. A total of 334 adults with AIDS or a CD4 cell count less than 200 cells/mm3 were assigned to acyclovir 4 g per day or placebo, combined with zidovudine 500 mg per day. Characteristics of enrollees and duration of follow-up were similar in each treatment group. One-hundred and six patients died. No differences in survival were seen between treatment groups in any analyses, including intent-to-treat analyses and exploratory analyses censoring data after study therapy was discontinued, or in the subset of enrollees with CD4 cell counts less than 100 cells/mm3 or less than 50 cells/mm3. Types and time to first AIDS-defining diseases were similar in both groups. There were significantly fewer episodes of varicella-zoster virus (P<0.0001) and herpes simplex virus (P=0.0001) infection in patients assigned to acyclovir/zidovudine than to zidovudine alone. Both regimens had similar tolerability. These data do not support routine use of acyclovir as a treatment for HIV-1 infection.

[1]  S. Hammer,et al.  Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. , 1997, JAMA.

[2]  Henry J. Kaiser,et al.  Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services and Henry J. Kaiser Family Foundation. , 1998, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[3]  J. Neaton,et al.  Acyclovir use and survival among human immunodeficiency virus-infected patients with CD4 cell counts of < 500/mm3. The Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  S. Hammer,et al.  Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. , 1998, JAMA.

[5]  N. Heveker,et al.  Identification of a chemokine receptor encoded by human cytomegalovirus as a cofactor for HIV-1 entry. , 1997, Science.

[6]  Roger Detels,et al.  Plasma Viral Load and CD4+ Lymphocytes as Prognostic Markers of HIV-1 Infection , 1997, Annals of Internal Medicine.

[7]  R. Chaisson,et al.  Acyclovir in combination with zidovudine does not prolong survival in advanced HIV disease. , 1997, Antiviral therapy.

[8]  J. Kahn,et al.  HIV-1 protease inhibitors. A review for clinicians. , 1997 .

[9]  J. Kahn,et al.  Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. AIDS Clinical Trials Group (ACTG) 116B/117 Study Team. ACTG Virology Committee Resistance and HIV-1 RNA Working Groups. , 1996, The Journal of infectious diseases.

[10]  J. Goedert,et al.  Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study. , 1996, JAMA.

[11]  Richard D Moore,et al.  Lack of Association between Acyclovir Use and Survival in Patients with Advanced Human Immunodeficiency Virus Disease Treated with Zidovudine , 1995 .

[12]  C. Sabin,et al.  The effect of CMV infection on progression of human immunodeficiency virus disease in a cohort of haemophilic men followed for up to 13 years from seroconversion , 1995, Epidemiology and Infection.

[13]  J. Phair,et al.  Prognostic factors in human immunodeficiency virus-positive patients with a CD4+ lymphocyte count < 50/microL. , 1995, The Journal of infectious diseases.

[14]  J. Phair,et al.  The Effect of the Interaction of Acyclovir with Zidovudine on Progression to AIDS and Survival: Analysis of Data in the Multicenter AIDS Cohort Study , 1994, Annals of Internal Medicine.

[15]  B. Gazzard,et al.  Effects of high‐dose oral acyclovir on herpesvirus disease and survival in patients with advanced HIV disease: a double‐blind, placebo‐controlled study , 1994 .

[16]  S. Allen,et al.  Co-infection and synergy of human immunodeficiency virus-1 and herpes simplex virus-1 , 1994, The Lancet.

[17]  D. Faulds,et al.  Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. , 1994, Drugs.

[18]  M. Moroni,et al.  The efficacy and safety of zidovudine alone or as cotherapy with acyclovir for the treatment of patients with AIDS and AIDS‐related complex: a double‐blind, randomized trial , 1993 .

[19]  S. Hammer,et al.  Activation of human immunodeficiency virus by herpes simplex virus. , 1992, The Journal of infectious diseases.

[20]  J. Pagano,et al.  Inhibition of Human Immunodeficiency Virus Type 1 Replication by Guanosine Analogues and Lack of Synergistic Antiviral Effect of Acyclovir with 3′-azido-3′-deoxythymidine , 1991 .

[21]  D. Richman,et al.  A pilot study of low-dose zidovudine in human immunodeficiency virus infection. , 1990, The New England journal of medicine.

[22]  J. Laurence,et al.  Molecular interactions among herpesviruses and human immunodeficiency viruses. , 1990, The Journal of infectious diseases.

[23]  P. Griffiths,et al.  CYTOMEGALOVIRUS INFECTION AND PROGRESSION TOWARDS AIDS IN HAEMOPHILIACS WITH HUMAN IMMUNODEFICIENCY VIRUS INFECTION , 1989, The Lancet.

[24]  M. Hirsch,et al.  Bidirectional interactions between human immunodeficiency virus type 1 and cytomegalovirus. , 1988, The Journal of infectious diseases.

[25]  D. Markovitz,et al.  An Epstein-Barr virus immediate-early gene product trans-activates gene expression from the human immunodeficiency virus long terminal repeat. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[26]  E. Huang,et al.  Immediate-early gene region of human cytomegalovirus trans-activates the promoter of human immunodeficiency virus. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[27]  P. Luciw,et al.  Transactivation of human immunodeficiency virus by herpesviruses. , 1987, Oncogene.

[28]  Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. Council of State and Territorial Epidemiologists; AIDS Program, Center for Infectious Diseases. , 1987, MMWR supplements.

[29]  H. Mitsuya,et al.  Strategies for antiviral therapy in AIDS , 1987, Nature.

[30]  J. Sodroski,et al.  Herpes simplex virus type-1 can reactivate transcription of latent human immunodeficiency virus , 1987, Nature.